Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803909 | 0.92 | KMT2A (0.59) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL4808050 | 0.89 | MEN1 (0.61) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL10968230 | 0.89 | MEN1 (0.61) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL3165362 | 0.89 | MEN1 (0.57) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL18760499 | 0.89 | MEN1 (0.57) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL20870697 | 0.87 | MEN1 (0.53) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL2118725 | 0.84 | MEN1 (0.59) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL6535265 | 0.84 | MEN1 (0.50) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL19762220 | 0.84 | MEN1 (0.50) | MEN1KMT2ANTSR1ADORA1ADORA2A | |
| SCHEMBL10168729 | 0.84 | CYP19A1 (0.62) | MEN1KMT2ANTSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| CN-105254637-A | PYRIMIDINE SUBSTITUTED MACROCYCLIC INHIBITORS | JANSSEN R & D IRELAND | 2016-01-20 | — | — | CN | disclosed |
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2007-02-08 | — | — | US | disclosed |
| EP-1667985-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | Universiteit Leiden (NL) | 2006-06-14 | — | — | EP | disclosed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005033084-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | UNIVERSITEIT LEIDEN (NL) | 2005-04-14 | — | — | WO | disclosed |
| US-20040110780-A1 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | MEN1 4470/4885KMT2A 4623/4885NTSR1 3269/4885 |
| US-20040110780-A1 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, GCKR | MEN1 4215/4885KMT2A 3613/4885NTSR1 376/4885 |
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | ADORA2A, ADORA3, ADORA1 | MEN1 4739/4885KMT2A 3074/4885NTSR1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.